688235 百济神州
午间休市 12-05 11:29:57
资讯
新帖
简况
百济神州(06160)授出合共2.13万个受限制股份单位
智通财经 · 12-04 16:53
百济神州(06160)授出合共2.13万个受限制股份单位
美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤
美股速递 · 11-26
美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤
每周股票复盘：百济神州（688235）获7亿美元授信及授出21.4万股股份
证券之星 · 11-23
每周股票复盘：百济神州（688235）获7亿美元授信及授出21.4万股股份
百济神州第三季度净利润达到6.888亿元
投资观察 · 11-20
百济神州第三季度净利润达到6.888亿元
百济神州 - 设施协议提供重启贷款额度140百万美元的以美元计价的B1轮融资
美股速递 · 11-19
百济神州 - 设施协议提供重启贷款额度140百万美元的以美元计价的B1轮融资
港股异动 | 百济神州(06160)高开逾3% 百赫安联合百泽安与化疗的3期临床研究取得积极结果
智通财经 · 11-18
港股异动 | 百济神州(06160)高开逾3% 百赫安联合百泽安与化疗的3期临床研究取得积极结果
百济神州 - Ziihera联合化疗临床试验仍在进行中，预计于2026年中期进行额外的生存分析
美股速递 · 11-17
百济神州 - Ziihera联合化疗临床试验仍在进行中，预计于2026年中期进行额外的生存分析
百济神州（688235）新增【基因编辑】概念
证券之星 · 11-17
百济神州（688235）新增【基因编辑】概念
每周股票复盘：百济神州（688235）Q3净利增185.11%
证券之星 · 11-16
每周股票复盘：百济神州（688235）Q3净利增185.11%
百济神州(06160)：授出合共1.65万股美国存托股份受限制股份单位
智通财经 · 11-14
百济神州(06160)：授出合共1.65万股美国存托股份受限制股份单位
百济神州(688235.SH)发布前三季度业绩，归母净利润11.39亿元，同比扭亏为盈
智通财经 · 11-12
百济神州(688235.SH)发布前三季度业绩，归母净利润11.39亿元，同比扭亏为盈
百济神州早盘涨超6% 泽布替尼在美国及欧洲市场放量超预期
新浪港股 · 11-12
百济神州早盘涨超6% 泽布替尼在美国及欧洲市场放量超预期
港股创新药概念股盘初活跃！百济神州涨近5%，歌礼制药涨超4%
老虎资讯综合 · 11-12
港股创新药概念股盘初活跃！百济神州涨近5%，歌礼制药涨超4%
海通国际：百济神州(06160)泽布替尼在美欧市场放量超预期 维持“优于大市”评级
智通财经 · 11-11
海通国际：百济神州(06160)泽布替尼在美欧市场放量超预期 维持“优于大市”评级
【机构调研记录】华宝基金调研泽璟制药、百济神州等3只个股（附名单）
证券之星 · 11-11
【机构调研记录】华宝基金调研泽璟制药、百济神州等3只个股（附名单）
股市必读：百济神州（688235）11月10日披露最新机构调研信息
证券之星 · 11-11
股市必读：百济神州（688235）11月10日披露最新机构调研信息
【券商聚焦】招银国际维持百济神州(06160)美股“买入”评级 指其盈利能力持续改善
金吾财讯 · 11-10
【券商聚焦】招银国际维持百济神州(06160)美股“买入”评级 指其盈利能力持续改善
百济神州第三季营收101亿：同比增41% 扣非后净利7亿
雷递网 · 11-10
百济神州第三季营收101亿：同比增41% 扣非后净利7亿
每周股票复盘：百济神州（688235）Q3营收100.77亿元同比增41.1%
证券之星 · 11-09
每周股票复盘：百济神州（688235）Q3营收100.77亿元同比增41.1%
大华继显：升百济神州目标价至252港元 维持“买入”评级
智通财经 · 11-07
大华继显：升百济神州目标价至252港元 维持“买入”评级
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":277.85,"timestamp":1764905397000,"preClose":280.23,"halted":0,"volume":646850,"delay":0,"changeRate":-0.0085,"floatShares":114999999,"shares":1541000000,"eps":-0.0994,"marketStatus":"午间休市","change":-2.38,"latestTime":"12-05 11:29:57","open":280.23,"high":280.23,"low":276.95,"amount":180000000,"amplitude":0.0117,"askPrice":277.91,"askSize":2,"bidPrice":277.85,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-0.0994,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1764910800000},"marketStatusCode":3,"adr":0,"adjPreClose":280.23,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":308.25,"lowLimit":252.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":14.72,"roa":"--","roe":"4.26%","epsLYR":-3.64,"committee":-0.647059,"marketValue":428077000000.0001,"turnoverRate":0.0056,"status":1,"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":197.5,"timestamp":1764906406694,"preClose":200.4,"halted":0,"volume":652742,"delay":0,"premium":"-35.45"},"floatMarketCap":31968000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2588002521","title":"百济神州(06160)授出合共2.13万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002521?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:53","pubTimestamp":1764838411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月28日，董事会薪酬委员会根据2016期权及激励计划的条款授予147名承授人合共2.13万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.66万股股份，约占本公告之日公司发行股份总数的0.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1303224171.USD","LU1969619763.USD","BK1500","BK0239","LU0307460666.USD","BK4139","LU0588546209.SGD","LU1770034418.SGD","688235","BK1588","ONC","LU2328871848.SGD","BK4526","06160","BK4585","LU1251922891.USD","LU1719994722.HKD","BK1161"],"gpt_icon":0},{"id":"1189770578","title":"美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1189770578","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189770578?lang=zh_cn&edition=full","pubTime":"2025-11-26 19:02","pubTimestamp":1764154944,"startTime":"0","endTime":"0","summary":"美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2585103603","title":"每周股票复盘：百济神州（688235）获7亿美元授信及授出21.4万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103603","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103603?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:32","pubTimestamp":1763836334,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，百济神州报收于278.88元，较上周的298.8元下跌6.67%。本周，百济神州11月18日盘中最高价报302.67元。公司公告汇总港股公告：授出受限制股份单位2025年11月10日，百济神州有限公司董事会薪酬委员会根据2016期权及激励计划，向143名承授人授出合计16,463股美国存托股份的受限制股份单位，涉及股份214,019股，约占公司已发行股份总数的0.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1588","LU1969619763.USD","BK1583","06160","LU1251922891.USD","LU1770034418.SGD","BK1500","688235","LU0307460666.USD","LU0588546209.SGD","BK1161","LU1303224171.USD","LU2328871848.SGD","LU1719994722.HKD"],"gpt_icon":0},{"id":"1137400071","title":"百济神州第三季度净利润达到6.888亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137400071","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137400071?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:56","pubTimestamp":1763571360,"startTime":"0","endTime":"0","summary":"11月6日 - 百济神州（BeOne Medicines AG）第三季度净利润为6.888亿元人民币（合9,670万美元）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"1144713366","title":"百济神州 - 设施协议提供重启贷款额度140百万美元的以美元计价的B1轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1144713366","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144713366?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:14","pubTimestamp":1763550876,"startTime":"0","endTime":"0","summary":"百济神州 - 设施协议提供重启贷款额度140百万美元的以美元计价的B1轮融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2584095566","title":"港股异动 | 百济神州(06160)高开逾3% 百赫安联合百泽安与化疗的3期临床研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2584095566","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584095566?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:25","pubTimestamp":1763429130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.53%，报223.2港元，成交额1196.27万港元。消息面上，11月17日，百济神州宣布III期HERIZON-GEA-01研究取得积极结果。中信建投此前指出，百济神州泽布替尼持续放量，上调全年业绩指引。考虑到公司BTK海外放量超预期，以及PD-1在欧盟、日本等其他国家上市放量，以及BCL-2、BTK CDAC、CDK4等重磅管线持续兑现带来商业化进一步兑现，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4fc0c44f8d8eb43e289164e52c59bade","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1303224171.USD","BK4526","LU0588546209.SGD","ONC","LU0307460666.USD","LU1251922891.USD","BK1583","BK4139","BK0239","LU1770034418.SGD","BK1588","BK1161","LU1719994722.HKD","06160","688235","BK1500","LU2328871848.SGD","BK4585","LU1969619763.USD"],"gpt_icon":0},{"id":"1154152521","title":"百济神州 - Ziihera联合化疗临床试验仍在进行中，预计于2026年中期进行额外的生存分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1154152521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154152521?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:01","pubTimestamp":1763377297,"startTime":"0","endTime":"0","summary":"百济神州 - Ziihera联合化疗的临床试验仍在进行中，预计于2026年中期进行额外的生存分析。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2584487886","title":"百济神州（688235）新增【基因编辑】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2584487886","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584487886?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:27","pubTimestamp":1763368077,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，11月17日百济神州新增概念。该公司关联的其它概念板块还包括：PD-1抑制剂、创新药、健康中国、医药。百济神州主营业务：研究、开发、生产以及商业化创新型药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700020696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","BK1588","BK1500","06160","LU1251922891.USD","LU1719994722.HKD","LU2328871848.SGD","LU0588546209.SGD","BK1161","LU1969619763.USD","BK1583","LU1303224171.USD","688235","LU1770034418.SGD","BK0239"],"gpt_icon":0},{"id":"2583560886","title":"每周股票复盘：百济神州（688235）Q3净利增185.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560886","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583560886?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:39","pubTimestamp":1763228348,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，百济神州报收于298.8元，较上周的279.0元上涨7.1%。本周，百济神州11月13日盘中最高价报313.25元。股本股东变化截至2025年9月30日，公司股东户数为3.6万户，较6月30日增加1.29万户，增幅55.74%。业绩披露要点百济神州2025年三季报显示，前三季度主营收入275.95亿元，同比上升44.21%；归母净利润11.39亿元，同比上升130.88%；扣非净利润9.69亿元，同比上升124.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1588","LU2328871848.SGD","BK1500","06160","688235","LU0307460666.USD","BK0239","LU1251922891.USD","BK1161","LU1719994722.HKD","LU0588546209.SGD","LU1303224171.USD","BK1583","LU1969619763.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2583041715","title":"百济神州(06160)：授出合共1.65万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2583041715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583041715?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:19","pubTimestamp":1763129941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月10日，董事会薪酬委员会根据2016期权及激励计划的条款授予143名承授人合共1.65万股美国存托股份受限制股份单位。该等受限制股份单位相当于21.4万股股份，约占本公告之日公司发行股份总数的0.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LU1303224171.USD","LU0307460666.USD","BK4526","BK1583","LU1251922891.USD","LU1770034418.SGD","LU1969619763.USD","BK1500","ONC","BK1588","BK0239","06160","BK1161","688235","LU1719994722.HKD","LU0588546209.SGD","LU2328871848.SGD","BK4585"],"gpt_icon":0},{"id":"2582324114","title":"百济神州(688235.SH)发布前三季度业绩，归母净利润11.39亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2582324114","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582324114?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:55","pubTimestamp":1762941355,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(688235.SH)披露2025年第三季度报告，公司前三季度实现营收275.95亿元，同比增长44.2%;归属于上市公司股东的净利润11.39亿元，同比扭亏为盈;扣非净利润9.69亿元，同比扭亏为盈;基本每股收益0.81元。业绩增长主要系由于产品收入增长和费用管理推动了经营效率的提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"3e29954d58cc28fb957aa030db20e76a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","688235","ONC"],"gpt_icon":0},{"id":"2582317338","title":"百济神州早盘涨超6% 泽布替尼在美国及欧洲市场放量超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2582317338","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582317338?lang=zh_cn&edition=full","pubTime":"2025-11-12 09:59","pubTimestamp":1762912740,"startTime":"0","endTime":"0","summary":" 百济神州早盘股价上涨6.08%，现报209.40港元，成交额7.25亿港元。 百济神州此前发布业绩，第三季度营收首破百亿元，达100.77亿元，同比增长41.1%。 交银国际发布研报称，百济神州第三季度产品收入14.1亿美元，同比增长41%。海通国际则表示，考虑到百济神州泽布替尼在美国及欧洲市场的放量超该行预期，故上调其2025-2027年收入预期至53亿/64亿/71亿美元，对应年均复合成长率为23%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-11-12/doc-infxccth6513285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","688235","LU0588546209.SGD","BK4526","LU1770034418.SGD","LU1251922891.USD","LU2328871848.SGD","BK1588","BK1500","ONC","BK4139","BK0239","BK1583","LU1969619763.USD","LU0307460666.USD","BK4585","LU1303224171.USD","BK1161","LU1719994722.HKD"],"gpt_icon":0},{"id":"1192151735","title":"港股创新药概念股盘初活跃！百济神州涨近5%，歌礼制药涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192151735","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192151735?lang=zh_cn&edition=full","pubTime":"2025-11-12 09:42","pubTimestamp":1762911738,"startTime":"0","endTime":"0","summary":"11月13日，港股创新药概念股盘初活跃，$百济神州(ONC)$涨近5%，$歌礼制药-B(01672)$涨超4%，$康方生物(09926)$涨超3%，$三生制药(01530)$、$乐普生物-B(02157)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3e29954d58cc28fb957aa030db20e76a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1719994722.HKD","01477","LU1251922891.USD","06978","BK1583","BK1191","ONC","BK1515","BK4526","LU1969619763.USD","BK1161","LU0307460666.USD","159992","BK4139","06160","688235","LU2328871848.SGD","BK0239","BK1574","LU1303224171.USD","LU1770034418.SGD","BK1588","LU0588546209.SGD","01672","BK1500"],"gpt_icon":0},{"id":"2582337112","title":"海通国际：百济神州(06160)泽布替尼在美欧市场放量超预期 维持“优于大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2582337112","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582337112?lang=zh_cn&edition=full","pubTime":"2025-11-11 14:25","pubTimestamp":1762842358,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，考虑到百济神州(06160)泽布替尼在美国及欧洲市场的放量超该行预期，故上调其2025-2027年收入预期至53亿/64亿/71亿美元，对应年均复合成长率为23%。该行同时上调百济神州归母净利润分别至3.6亿/6.6亿/10.5亿美元，以反映集团销售费用及研发费用增长优于预期。基于9%的加权平均资本成本及4%的永续增长率，对应集团目标价为213.1港元，维持“优于大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2582538121","title":"【机构调研记录】华宝基金调研泽璟制药、百济神州等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2582538121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582538121?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:05","pubTimestamp":1762819525,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月10日披露的机构调研信息，华宝基金近期对3家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：2025年前三季度，公司实现营收59,344.01万元，同比增长54.49%，主要因药品销售增长。ZGGS34获中美临床批准。研发费用为30,277.87万元，保持平稳。CDK4抑制剂聚焦一线乳腺癌研究，推迟披露二线数据。3）苏大维格 调研纪要：常州维普主营光掩模和晶圆缺陷检测设备，属半导体量检测核心设备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100004220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1770034418.SGD","BK1583","BK1500","LU1719994722.HKD","688235","LU2328871848.SGD","BK1161","LU0307460666.USD","BK1588","LU1251922891.USD","LU1969619763.USD","688266","LU1303224171.USD","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2582019298","title":"股市必读：百济神州（688235）11月10日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2582019298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582019298?lang=zh_cn&edition=full","pubTime":"2025-11-11 02:27","pubTimestamp":1762799230,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，百济神州报收于280.16元，上涨0.42%，换手率2.7%，成交量3.1万手，成交额8.55亿元。维奈克拉在MM中因安全性影响总生存期而受限，百济神州BCL2抑制剂有望克服此问题。CDK4抑制剂二线剂量与一线高度相关，为避免干扰一线剂量选择，公司推迟披露后线治疗数据。目前乳腺癌辅助治疗占比偏低，未来预计持续增长。百悦泽用于膜性肾病的三期临床试验正在进行，注册可能性正被评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","BK1588","BK1500","06160","LU1251922891.USD","LU1719994722.HKD","LU2328871848.SGD","LU0588546209.SGD","BK1161","LU1969619763.USD","BK1583","LU1303224171.USD","688235","LU1770034418.SGD","BK0239"],"gpt_icon":0},{"id":"2582841829","title":"【券商聚焦】招银国际维持百济神州(06160)美股“买入”评级 指其盈利能力持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2582841829","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582841829?lang=zh_cn&edition=full","pubTime":"2025-11-10 13:37","pubTimestamp":1762753053,"startTime":"0","endTime":"0","summary":"Zanu 与Sonrotoclax组合的一线CLL固定疗程方案，以及在BTK耐药CLL中的BTK CDAC方案的持续推进，有望进一步巩固百济神州在血液肿瘤领域的领先地位。该机构维持对百济神州的“买入”评级，目标价上调至392.43美元。继1Q25实现公司历史上首个GAAP净利润后，百济神州在3Q25净利润增长至1.25亿美元，得益于强劲的收入增长和GAAP层面的运营杠杆改善。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969311","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2582889846","title":"百济神州第三季营收101亿：同比增41% 扣非后净利7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2582889846","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582889846?lang=zh_cn&edition=full","pubTime":"2025-11-10 12:28","pubTimestamp":1762748888,"startTime":"0","endTime":"0","summary":"百济神州有限公司（股份代号：06160）日前发布截至2025年9月30日的财报。财报显示，百济神州2025年前9个月营收为275.95亿元，同比增长44.2%；运营利润为15.45亿元，归属于母公司所有者的净利润为11.39亿元，扣非后净利为9.69亿元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251110/6389837448203772395532319.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251110/6389837448203772395532319.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31711/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688235","06160","ONC"],"gpt_icon":0},{"id":"2582666018","title":"每周股票复盘：百济神州（688235）Q3营收100.77亿元同比增41.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582666018","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582666018?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:42","pubTimestamp":1762623733,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，百济神州报收于279.0元，较上周的296.75元下跌5.98%。本周关注点公司公告汇总：百济神州上调2025年营收预测至362亿至381亿元。业绩披露要点：2025年第三季度营业总收入达100.77亿元，同比增长41.1%。公司公告汇总：百悦泽全球销售额达74.23亿元，同比增长51.0%。公司公告汇总百济神州有限公司将于2025年11月14日通过上证路演中心召开2025年第三季度业绩说明会，介绍经营成果并回答投资者提问。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160"],"gpt_icon":0},{"id":"2581767008","title":"大华继显：升百济神州目标价至252港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581767008?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:20","pubTimestamp":1762507200,"startTime":"0","endTime":"0","summary":"大华继显发布研报称，百济神州(06160)第三季营收升43.3%至38亿美元，经调整净利6.93亿美元，胜该行及市场预期。公司上调2025年营收指引，并略微调降成本预测。BRUKINSA强劲的销售前景与营运 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251107/c672323764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764906410154,"stockEarnings":[{"period":"1week","weight":-0.0229},{"period":"1month","weight":0.0283},{"period":"3month","weight":-0.1237},{"period":"6month","weight":0.189},{"period":"1year","weight":0.6238},{"period":"ytd","weight":0.7403}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0166},{"period":"6month","weight":0.1449},{"period":"1year","weight":0.1519},{"period":"ytd","weight":0.1563}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36008人(较上一季度增加55.74%)","perCapita":"3195股","listingDate":"2021-12-15","address":"c/o BeOne Medicines I GmbH, Aeschengraben 27, 4051 Basel, Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}